Hinge Health CEO Daniel Perez disposes of $22.3 million in company stock By Investing.com

Daniel Antonio Perez, CEO and Co-Founder of Hinge Health, Inc. (), along with his spouse, disposed of Class A Common Stock totaling approximately $22.3 million on September 10, 2026. These transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on June 11, 2026. The timing coincides with the stock trading near its 52-week high of $95.57, following a remarkable 99% surge over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, and is one of 14 additional ProTips available to subscribers, alongside comprehensive Pro Research Reports covering 1,400+ US equities.

Mr. Perez directly sold 99,000 shares of Class A Common Stock, while an additional 150,000 shares were sold indirectly by his spouse. The shares were sold across multiple transactions at prices ranging from $87.44 to $91.76 per share. In total, 249,000 shares of Class A Common Stock were sold.

On the same date, Mr. Perez also acquired Class A Common Stock through conversions of Class B Common Stock. He directly converted 145,000 shares of Class B Common Stock into an equal number of Class A Common Stock. An additional 150,000 shares of Class B Common Stock were converted into Class A Common Stock indirectly by his spouse. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at no additional cost. Furthermore, Mr. Perez disposed of 45,000 shares of Class A Common Stock in a transaction identified as a gift.

In other recent news, Hinge Health reported stronger-than-expected second-quarter results, with earnings per share of $0.59, significantly surpassing Wall Street’s estimate of $0.13. The company’s revenue rose 53% from the previous year to $212.8 million, demonstrating considerable growth. Following these results, Hinge Health raised its full-year 2026 revenue and profit guidance, reflecting confidence in its business trajectory. The company also announced plans to expand into the gastrointestinal health sector with a $105 million acquisition of Cylinder Health. This move was highlighted by Citizens, who raised their price target for Hinge Health shares to $107 from $96.

Additionally, Stifel increased its price target to $115, citing a strong growth outlook, and Truist Securities adjusted their target to $112, reflecting the company’s revised earnings outlook and the pending acquisition. Stifel had previously raised its target to $96 due to the company’s outperformance. These developments underscore the positive sentiment among analysts regarding Hinge Health’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.